Ken Peh
★    

Malaysia,
2013-06-05 15:30
(4767 d 14:37 ago)

Posting: # 10728
Views: 2,925
 

 Acarbose BE study [Design Issues]

Dear All,

According to Draft Guidance on Acarbose, a pilot study should first be conducted to determine the appropriate dose for the pivotal BE study. The first dose tested should be the RLD 1*25mg tablet.

The sponsor has two strengths of 50 mg and 100 mg.

Since the sponsor does not have 25 mg, can we start with 100 mg and revert back to 50 mg if we see effect in 100 mg ? We search the literature and found that the effect could hardly be seen in 50mg. The sponsor suggests to run 100 mg first. If no effect, proceeds to 150 mg.

Your comment is highly appreciated.

Thank you.

Regards,
Ken


Edit: Guidance linked. [Helmut]
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
104 visitors (0 registered, 104 guests [including 9 identified bots]).
Forum time: 06:07 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5